Feasibility of using medication adherence scale in clozapine patients

  • Research type

    Research Study

  • Full title

    Feasibility of introducing medication Adherence Rating Scale (ARS) in clozapine clinic

  • IRAS ID

    242041

  • Contact name

    Asta Ratna Prajapati

  • Contact email

    asta.prajapati@nsft.nhs.uk

  • Sponsor organisation

    Norfolk and Suffolk NHS Foundation Trust

  • Clinicaltrials.gov Identifier

    18/LO/1018, London - Harrow Research Ethics Committee

  • Duration of Study in the UK

    1 years, 0 months, 28 days

  • Research summary

    About half the populations living with chronic mental health conditions do not adhere to their prescribed medication direction. Medication non-adherence (generally defined as taking <80% of prescribed doses) is the most common cause of relapse in mental health disorder. In the UK, Department of Health estimates that non-adherence to medication is costing NHS £500 million per year (2011). Thus, improving medication adherence is of significant clinical importance and huge economic benefits.

    The identification of non-adherent service user is the first critical part in dealing with adherence problem and associated relapses. Medication Adherence Rating Scale (ARS) are non-invasive, simple, cheap and easy to use and can be embedded in routine clinical practice.

    Many medication ARS exists including Medication Adherence Scale(MARS), Drug Attitudes Questionnaire (DAI), Brief Adherence Rating Scale (BARS). Some have been shown to identify non-adherent service users diagnosed with schizophrenia and/or schizoaffective disorders. However, systematic assessment of non-adherence using validated medication ARS in clinical practice is rare. In addition, a very limited feasibility and acceptability work with end users i.e. patients and practitioners are reported.

    We plan to investigate the feasibility of using ARS in patients prescribed clozapine. From the study we will be able to estimate the response rates, completion rates, identify barriers or difficulties in completing the ARS and explore patients’ acceptability to using ARS. We will also test the feasibility of correlating ARS with objective adherence measures such as blood plasma level, Medication Possession Ratio (MPR, The number of dispensed medication doses divided by the number of days in a unit of time).

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference

    18/LO/1018

  • Date of REC Opinion

    12 Jul 2018

  • REC opinion

    Further Information Favourable Opinion